What is Ocular Therapeutix's financing cash flow?

Ocular Therapeutix (OCUL) reported financing cash flow of $294K in Q1 2026.

How has Ocular Therapeutix's financing cash flow changed year-over-year?

Ocular Therapeutix's financing cash flow decreased by 93.0% year-over-year, from $4.18M to $294K.

What is the long-term trend for Ocular Therapeutix's financing cash flow?

Over 4 years (2021 to 2025), Ocular Therapeutix's financing cash flow has grown at a 274.7% compound annual growth rate (CAGR), from $2.85M to $561.72M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ocular Therapeutix OCUL Financing Cash Flow

Financing Cash Flow at other companies

Regeneron PharmaceuticalsREGN

-$802.2M+26.3%

Bausch + LombBLCO

-$20M-165%

HRO

HarrowHROW

$48.91M+212,561%

Tarsus Pharmaceuticals, Inc.TARS

$1.2M-99.1%

Kodiak Sciences IncKOD

$619K+399%

PBH

Prestige Consumer HealthcarePBH

-$38.1M-232%

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's financing cash flow?: Ocular Therapeutix (OCUL) reported financing cash flow of $294K in Q1 2026.
How has Ocular Therapeutix's financing cash flow changed year-over-year?: Ocular Therapeutix's financing cash flow decreased by 93.0% year-over-year, from $4.18M to $294K.
What is the long-term trend for Ocular Therapeutix's financing cash flow?: Over 4 years (2021 to 2025), Ocular Therapeutix's financing cash flow has grown at a 274.7% compound annual growth rate (CAGR), from $2.85M to $561.72M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.